COMMUNIQUÉS West-GlobeNewswire
-
Clareo Plastic Surgery Named Best Plastic Surgery Practice in Boston
06/07/2026 -
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
06/07/2026 -
Cosmos Health Share Buyback Increases to 3.64 Million Shares; Continues Open Market Purchases
06/07/2026 -
Alberta Cancer Foundation invests $35-million to power cancer clinical trials for Albertans
06/07/2026 -
NewGen’s Advanced Cytometry Platform Poised for Major UAE/GCC Expansion with Big Four Valuation of US$19 Million
06/07/2026 -
Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)
06/07/2026 -
IPSEN - Buy-back programme - Art 5 of MAR - Week 27- 2026
06/07/2026 -
MESA LABS DECLARES QUARTERLY DIVIDEND
06/07/2026 -
Correction: Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on August 3, 2026
06/07/2026 -
Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026
06/07/2026 -
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 27 - 2026
06/07/2026 -
FOXO TECHNOLOGIES INC. CEO SEAMUS LAGAN PROVIDES MID-YEAR UPDATE TO SHAREHOLDERS
06/07/2026 -
PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset
06/07/2026 -
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
06/07/2026 -
Canada Diagnostic Centres, a Novacap Portfolio Company, Announces Acquisition of Shift Imaging
06/07/2026 -
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
06/07/2026 -
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
06/07/2026 -
GuideAI Health Appoints Renowned Interventional Radiologist Dr. James Benenati to Advisory Board Following FDA 510(k) Clearance of VAOT
06/07/2026 -
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
06/07/2026
Pages